[Skip to content]

NHS
Loading
.

Anti-cancer medicines

Reference number
1134
Issue date28 October 2010
TypeGuidance

The National Patient Safety Agency (NPSA) regularly undertakes themed reviews of patient safety incident reports to better understand risks in a specified area of practice and identify actions and strategies to minimise preventable harms to patients. Patient safety incident reports involving anti-cancer medicines reported between 1 November 2003 and 30 June 2008 were selected for review.

 

The term ‘anti-cancer medicines’ has been used throughout to encompass conventional cytotoxic and cytostatic medicines, as well as newer biological treatments such as monoclonal antibodies, so-called ‘small molecules’, and other targeted therapies.

 

Patient safety incident reports which described the non-cancer use of anti-cancer medicines, predominantly involving the use of methotrexate to modify the immune response in rheumatology and dermatology, were excluded from the review. The remaining reports were analysed by clinical outcome, stage of the medicines use process, type of incident, and anti-cancer medicine.


 

Anticancer themed review executive summary
Anticancer themed review executive summary - 157 KB 1134 | Anticancer themed review executive summary | Anticancer themed review | 2010-08-26 | v1
Anticancer themed review full report
Anticancer themed review full report - 259 KB 1134 A | Anticancer themed review full report | Anticancer themed review | 2010-08-26 | v1
Anticancer themed review appendix
Anticancer themed review appendix - 336 KB 1134 B | Anticancer themed review appendix | Anticancer themed review | 2010-08-26 | v1
Recommendation 1 Example of a protocol review checklist
Recommendation 1 Example of a protocol review checklist - 100 KB 1134 C | Recommendation 1 Example of a protocol review checklist | Anticancer themed review | 2010-08-26 | v1
Recommendation 2 Example guidelines prescribing admin of cytotoxic drugs
Recommendation 2 Example guidelines prescribing admin of cytotoxic drugs - 1.45 MB 1134 D | Recommendation 2 Example guidelines prescribing admin of cytotoxic drugs | Anticancer themed review | 2010-08-26 | v1
Recommendation 4 Example cytotoxic and support care prescription form
Recommendation 4 Example cytotoxic and support care prescription form - 100 KB 1134 E | Recommendation 4 Example cytotoxic and support care prescription form | Anticancer themed review | 2010-08-26 | v1
Recommendation 5 Example cytotoxic protocols for electronic systems
Recommendation 5 Example cytotoxic protocols for electronic systems - 129 KB 1134 F | Recommendation 5 Example cytotoxic protocols for electronic systems | Anticancer themed review | 2010-08-26 | v1
Recommendation 6 Anticancer Example TPlan
Recommendation 6 Anticancer Example TPlan - 108 KB 1134 G | Recommendation 6 Anticancer Example TPlan | Anticancer themed review | 2010-08-26 | v1
Recommendation 7 Example Infusion monitoring form
Recommendation 7 Example Infusion monitoring form - 157 KB 1134 H | Recommendation 7 Example Infusion monitoring form | Anticancer themed review | 2010-08-26 | v1
Recommendation 8 Example toxicity leaflet for patients and A&E staff
Recommendation 8 Example toxicity leaflet for patients and A&E staff - 46 KB 1134 I | Recommendation 8 Example toxicity leaflet for patients and A&E staff | Anticancer themed review | 2010-08-26 | v1